Cited by 2,833Heart Failure Treatment and ManagementHeart rate and cardiovascular healthCardiovascular Function and Risk Factors

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Open access

Cohn, Jay N., Johnson, Gary, Ziesche, Susan, Cobb, Frederick, Francis, Gary, Tristani, Felix, Smith, Raphael, Dunkman, W. Bruce, Loeb, Henry, Wong, Maylene, Bhat, Geetha, Goldman, Steven, Fletcher, Ross D., Doherty, James, Hughes, C. Vincent, Carson, Peter, Cintron, Guillermo, Shabetai, Ralph, Haakenson, Clair·1991·New England Journal of Medicine

DOI 10.1056/nejm199108013250502

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure. The patients were randomly assigned in a double-blind manner to receive 20 mg of enalapril daily or 300 mg of hydralazine plus 160 mg of isosorbide dinitrate daily. The latter regimen was identical to that used with a similar patient population in the effective-treatment arm of our previous Vasodilator-Heart Failure Trial. RESULTS: Mortality after two years was significantly lower in the enalapril arm (18 percent) than in the hydralazine-isosorbide dinitrate arm (25 percent) (P = 0.016; reduction in mortality, 28.0 percent), and overall mortality tended to be lower (P = 0.08). The lower mortality in the enalapril arm was attributable to a reduction in the incidence of sudden death, and this beneficial effect was more prominent in patients with less severe symptoms (New York Heart Association class I or II). In contrast, body oxygen consumption at peak exercise was increased only by hydralazine-isosorbide dinitrate treatment (P less than 0.05), and left ventricular ejection fraction, which increased with both regimens during the 2 years after randomization, increased more (P less than 0.05) during the first 13 weeks in the hydralazine-isosorbide dinitrate group. CONCLUSIONS: The similar two-year mortality in the hydralazine-isosorbide dinitrate arms in our previous Vasodilator-Heart Failure Trial (26 percent) and in the present trial (25 percent), as compared with that in the placebo arm in the previous trial, (34 percent) and the further survival benefit with enalapril in the present trial (18 percent) strengthen the conclusion that vasodilator therapy should be included in the standard treatment for heart failure. The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199108013250502

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,109
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citation
A placebo-controlled trial of captopril in refractory chronic congestive heart failure
Captopril Multicenter Research Group (1983) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(83)80316-7 · Cited by 588
Vasodilator Therapy of Cardiac Failure
Cohn, J. N., & Franciosa, J. A. (1977) · New England Journal of Medicine · doi:10.1056/nejm197707072970105 · Cited by 483
Self-citation
The role of vasodilator therapy in heart failure
Chatterjee, K., & Parmley, W. W. (1977) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(77)90006-8 · Cited by 315
Vasodilator Therapy for Heart Failure
Cohn, J. N. (1973) · Circulation · doi:10.1161/01.cir.48.1.5 · Cited by 293
Self-citation
Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.
Leier, C. V., Huss, P., Magorien, R. D., & Unverferth, D. V. (1983) · Circulation · doi:10.1161/01.cir.67.4.817 · Cited by 289

Show all 19 references

Research works printed but not linked: 1

Cohn, 1987, Circulation, 76, IV–443

Sorted by citations

Items 301–400 of 1,000

‘Time is Prognosis’ in Heart Failure: Time-to-Treatment Initiation as a Modifiable Risk Factor
Abdin, A., Anker, S. D., Butler, J., Coats, A. J. S., Kindermann, I., Lainščak, M., Lund, L. H., Metra, M., Müllens, W., Rosano, G. M. C., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13646 · Cited by 137
A multicenter disease management program for hospitalized patients with heart failure
Tsuyuki, R. T., Fradette, M., Johnson, J. A., Bungard, T. J., Eurich, D. T., Ashton, T., Gordon, W., Ikuta, R. M., Kornder, J. M., Mackay, E., et al. (2004) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2004.02.005 · Cited by 132
Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency
Atkins, C. E., Keene, B. W., Brown, W. A., Coats, J. R., Crawford, M. A., DeFrancesco, T. C., Edwards, N. J., Fox, P. R., Lehmkuhl, L. B., Luethy, M. W., et al. (2007) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.231.7.1061 · Cited by 137
Chronic Heart Failure
Morrissey, R. P., Czer, L. S. C., & Shah, P. K. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11592090-000000000-00000 · Cited by 131
Changing Characteristics and Mode of Death Associated With Chronic Heart Failure Caused by Left Ventricular Systolic Dysfunction
Cubbon, R. M., Gale, C. P., Kearney, L. C., Schechter, C. B., Brooksby, W. P., Nolan, J., Fox, K. A. A., Rajwani, A., Baig, W., Groves, D., et al. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.110.959882 · Cited by 132
Heart Failure in Women
Bozkurt, B., & Khalaf, S. Z. (2017) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-13-4-216 · Cited by 137
Sudden Cardiac Death in Heart Failure
Marbán, E., & Tomaselli, G. F. (1998) · Medical science symposia series · doi:10.1007/978-94-011-5022-4_40 · Cited by 130
Rationale, design, implementation, and baseline characteristics of patients in the dig trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure
The Digitalis Investigation Group (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00065-8 · Cited by 133
Rapid Cardiotonic Effects of Lipid Emulsion Infusion*
Fettiplace, M. R., Ripper, R. L., Lis, K., Lin, B., Lang, J., Zider, B., Wang, J., Rubinstein, I., & Weinberg, G. L. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e318287f874 · Cited by 130
Practical Recommendations for the Use of ACE Inhibitors, Beta-Blockers, Aldosterone Antagonists and Angiotensin Receptor Blockers in Heart Failure: Putting Guidelines into Practice
McMurray, J. J. V., Solal, A. C., Dietz, R., Eichhorn, E. J., Erhardt, L., Hobbs, R. F., Krum, H., Maggioni, A. P., McKelvie, R. S., Piña, I. L., et al. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.07.002 · Cited by 130
Repolarization dispersion and sudden cardiac death in patients with impaired left ventricular function
Fu, G.-S., Meissner, A., & Simon, R. G. (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015232 · Cited by 129
Direct Renin Inhibition in Addition to or as an Alternative to Angiotensin Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale and Design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) Study
Krum, H., Massie, B. M., Abraham, W. T., Dickstein, K., Køber, L., McMurray, J. J. V., Desai, A., Gimpelewicz, C. R., Kandra, A., Reimund, B., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq212 · Cited by 129
Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations
Klein, L., O’Connor, C. M., Gattis, W. A., Zampino, M., Luca, L. D., Vitarelli, A., Fedele, F., & Gheorghiade, M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03336-2 · Cited by 130
Aldosterone and Myocardial Fibrosis in Heart Failure
Brilla, C. G. (2000) · Herz · doi:10.1007/s000590050024 · Cited by 135
ACE-inhibitor use and the long-term risk of renal failure in diabetes
Suissa, S., Hutchinson, T., Brophy, J. M., & Kezouh, A. (2006) · Kidney International · doi:10.1038/sj.ki.5000159 · Cited by 128
Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease
Petrie, M. C., Padmanabhan, N., McDonald, J. E., Hillier, C., Connell, J., & McMurray, J. J. V. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01111-1 · Cited by 129
Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks
Hall, J. L., Grindle, S. M., Han, X., Fermin, D. R., Park, S., Chen, Y., Bache, R. J., Mariash, A., Guan, Z., Ormaza, S., et al. (2004) · Physiological Genomics · doi:10.1152/physiolgenomics.00004.2004 · Cited by 127
Joint British recommendations on prevention of coronary heart disease in clinical practice
Cheesman, M., Leech, G. J., Chambers, J. B., Monaghan, M. J., & Nihoyannopoulos, P. (1998) · Heart · doi:10.1136/hrt.80.2008.1s · Cited by 176
Congenital heart disease: the original heart failure syndrome
Bolger, A. P. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00005-8 · Cited by 128
Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure
Zugck, C., Haunstetter, A., Krüger, C., Kell, R., Schellberg, D., Kübler, W., & Haass, M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01840-5 · Cited by 125
Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals
Philbin, E. F., Andreou, C., Rocco, T. A., Lynch, L. J., & Baker, S. L. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89177-1 · Cited by 125
Clinical Pharmacokinetics and Selective Pharmacodynamics of New Angiotensin Converting Enzyme Inhibitors
Song, J., & White, C. M. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241030-00005 · Cited by 124
Bradykinin Contributes to the Vasodilator Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure
Witherow, F. N., Helmy, A., Webb, D. J., Fox, K. A. A., & Newby, D. E. (2001) · Circulation · doi:10.1161/hc4301.098252 · Cited by 124
Resource Use and Survival of Patients Hospitalized with Congestive Heart Failure: Differences in Care by Specialty of the Attending Physician
Auerbach, A. D., Hamel, M. B., Davis, R. B., Connors, A. F., Regueiro, C. R., Desbiens, N. A., Goldman, L., Califf, R. M., Dawson, N. V., Wenger, N. S., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-3-200002010-00004 · Cited by 124
Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure
Aronow, W. S. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000175289.87583.e5 · Cited by 124
Heart Rate Is a Marker of Amiodarone Mortality Reduction in Severe Heart Failure
Nul, D. R., Doval, H. C., Grancelli, H., Varini, S. D., Soifer, S., Perrone, S. V., Prieto, N. D. C. T., & Scapín, O. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00066-1 · Cited by 123
Reinventing the ACE inhibitors: some old and new implications of ACE inhibition
Hanif, K., Bid, H. K., & Konwar, R. (2009) · Hypertension Research · doi:10.1038/hr.2009.184 · Cited by 126
A Review of Quality-of-Life Evaluations in Patients with Congestive Heart Failure
Berry, C., & McMurray, J. J. V. (1999) · PharmacoEconomics · doi:10.2165/00019053-199916030-00003 · Cited by 123
Heart rate variability - a therapeutic target?
Routledge, H., Chowdhary, S., & Townend, J. (2002) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2002.00404.x · Cited by 120
Angiotensin-Converting Enzyme Inhibitors
Izzo, J. L., & Weir, M. R. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00508.x · Cited by 124
Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway.
Zisman, L. S., Abraham, W. T., Meixell, G. E., Vamvakias, B. N., Quaife, R. A., Lowes, B. D., Roden, R. L., Peacock, S. J., Groves, B. Μ., & Raynolds, M. V. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118186 · Cited by 122
The cardiovascular dysmetabolic syndrome
Fagan, T. C., & DEEDWANIA, P. C. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00216-2 · Cited by 121
Phosphodiesterase III inhibitors for heart failure
Amsallem, E., Kasparian, C., Haddour, G., Boissel, J., & Nony, P. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002230.pub2 · Cited by 124
Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure
Packer, M., The Principal Investigators of the Reflect Study, Narahara, K. A., Elkayam, U., Sullivan, J. M., Pearle, D. L., Massie, B. M., & Creager, M. A. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90816-j · Cited by 119
Clinical Characteristics and Prognosis of Hospitalized Patients With Congestive Heart Failure
Tsuchihashi, M., Tsutsui, H., Kodama, K., Kasagi, F., & Takeshita, A. (2000) · Japanese Circulation Journal-english Edition · doi:10.1253/jcj.64.953 · Cited by 119
Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients
Nony, P., Boissel, J., Lièvre, M., Leizorovicz, A., Haugh, M. C., Fareh, S., & Breyne, B. D. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00192547 · Cited by 118
Basic statistics for clinicians: 2. Interpreting study results: confidence intervals.
Guyatt, G. H., Jaeschke, R., Heddle, N. M., Cook, D., Shannon, H. S., & Walter, S. D. (1995) · Europe PMC (PubMed Central) · Cited by 118
Basic statistics for clinicians: 1. Hypothesis testing.
Guyatt, G. H., Jaeschke, R., Heddle, N. M., Cook, D., Shannon, H. S., & Walter, S. D. (1995) · Europe PMC (PubMed Central) · Cited by 118
DITPA (3,5-Diiodothyropropionic Acid), a Thyroid Hormone Analog to Treat Heart Failure: Phase II Trial Veterans Affairs Cooperative Study
Goldman, S., McCarren, M., Morkin, E., Ladenson, P. W., Edson, R., Warren, S., Ohm, J., Thai, H., Churby, L., Barnhill, J., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.834424 · Cited by 117
Self-citation
Cardiac troponins in congestive heart failure
Carlo, C. H. D., & O’Connor, C. M. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70178-x · Cited by 117
I Diretriz Latino-Americana para avaliação e conduta na insuficiência cardíaca descompensada
Bocchi, E. A., Vilas‐Boas, F., Perrone, S. V., Caamaño, A. G., Clausell, N., Moreira, M. D. C. V., Thierer, J. M., Grancelli, H., Junior, C. V. S., de Albuquerque, D. C., et al. (2005) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2005002200001 · Cited by 115
Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005)
de Diagnóstico, G. D. T., & de Cardiología, T. D. L. I. C. C. D. L. S. E. (2005) · Revista Española de Cardiología · doi:10.1157/13078554 · Cited by 113
Frequent Non-Cardiac Comorbidities in Patients with Chronic Heart Failure
Dahlström, U. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.01.008 · Cited by 114
Drug discovery for heart failure: a new era or the end of the pipeline?
Kaye, D. M., & Krum, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2219 · Cited by 114
Eplerenone: A Selective Aldosterone Receptor Antagonist (SARA)
Delyani, J. A., Rocha, R., Cook, C. S., Tolbert, D. S., Levin, S., Roniker, B., Workman, D. L., Sing, Y. L., & Whelihan, B. (2001) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2001.tb00064.x · Cited by 113
Mechanical cardiac support 2000: current applications and future trial design
Stevenson, L. W., & Kormos, R. L. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01099-8 · Cited by 112
Role of Cytokines in the Mechanism of Action of Amlodipine: The PRAISE Heart Failure Trial
Mohler, E. R., Sorensen, L. C., Ghali, J. K., Schocken, D. D., Willis, P. W., Bowers, J. A., Cropp, A. B., & Pressler, M. L. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00145-9 · Cited by 111
Peripartum cardiomyopathy: A comprehensive review
Brown, C. S., & Bertolet, B. D. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)80034-3 · Cited by 111
Coronary artery bypass surgery as treatment for ischemic heart failure: the predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome
Pagano, D., Townend, J., Littler, W. A., Horton, R., Camici, P. G., & Bonser, R. S. (1998) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(98)70357-5 · Cited by 110
Costs and Effectiveness of Angiotensin Converting Enzyme Inhibition in Patients With Congestive Heart Failure
Paul, S. D. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420100129016 · Cited by 109
Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction
Benedict, C. R., Francis, G. S., Shelton, B. J., Johnstone, D. E., Kubo, S. H., Kirlin, P. C., Nicklas, J. M., Liang, C., Konstam, M. A., Greenberg, B., et al. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80748-6 · Cited by 110
Self-citation
BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective
Temple, R., & Stockbridge, N. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-1-200701020-00010 · Cited by 110
Heart Failure in African Americans
Yancy, C. W. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.028 · Cited by 108
Low incidence of stroke in ambulatory patients with heart failure: A prospective study
Katz, S. D., Marantz, P. R., Biasucci, L. M., Jondeau, G., Lee, K., Brennan, C., & LeJemtel, T. H. (1993) · American Heart Journal · doi:10.1016/s0002-8703(07)80021-4 · Cited by 108
Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction
Sanbe, A., Tanonaka, K., Kobayashi, R., & Takeo, S. (1995) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(95)91551-6 · Cited by 108
I Diretriz Brasileira de Cardio-Oncologia da Sociedade Brasileira de Cardiologia
Filho, R. K., Hajjar, L., Bacal, F., Hoff, P. M., Estevez-Diz, M. D. P., & Galas, F. (2011) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2011000700001 · Cited by 108
Myocardial electrical propagation in patients with idiopathic dilated cardiomyopathy.
Anderson, K. P., Walker, R. A. J., Urie, P. M., Ershler, P. R., Lux, R. L., & Karwandee, S. V. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116540 · Cited by 107
African-American Heart Failure Trial (A-HeFT): Rationale, design, and methodology
Franciosa, J. A., Taylor, A. L., Cohn, J. N., Yancy, C. W., Ziesche, S., Olukotun, A. Y., Ofili, E., Ferdinand, K. C., Loscalzo, J., & Worcel, M. (2002) · Journal of Cardiac Failure · doi:10.1054/jcaf.2002.124730 · Cited by 107
Self-citation
Optimizing therapy for complex or refractory heart failure: A management algorithm
Stevenson, L. W., Massie, B. M., & Francis, G. S. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70257-1 · Cited by 107
Self-citation
Etiology and response to drug treatment in heart failure
Folláth, F., Cleland, J. G. F., Klein, W., & Murphy, R. L. W. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00400-8 · Cited by 106
Angiotensin-Converting Enzyme Inhibitor Associated Cough: Deceptive Information from the Physicians' Desk Reference
Bangalore, S., Kumar, S., & Messerli, F. H. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.06.014 · Cited by 106
Radiofrequency Catheter Ablation of Sustained Ventricular Tachycardia in Idiopathic Dilated Cardiomyopathy
Kottkamp, H., Hindricks, G., Chen, X., Brunn, J., Willems, S., Haverkamp, W., Block, M. S., BREITHARDT, G. E., & Borggrefe, M. (1995) · Circulation · doi:10.1161/01.cir.92.5.1159 · Cited by 107
Signaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 108
Sympathetic Activation in Heart Failure and Its Treatment With β-Blockade
Pepper, G. S., & Lee, R. W. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.3.225 · Cited by 104
Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction
Jeejeebhoy, F. M., Keith, M. E., Freeman, M. R., Barr, A., McCall, M., Kurian, R., Mazer, C. D., & Errett, L. E. (2002) · American Heart Journal · doi:10.1067/mhj.2002.121927 · Cited by 104
Anticoagulation in Dilated Cardiomyopathy
Koniaris, L. S., & Goldhaber, S. Z. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00003-5 · Cited by 104
The hibernating myocardium: implications for management of congestive heart failure
Bonow, R. O. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80379-8 · Cited by 104
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure
Emdin, M., Aimo, A., Castiglione, V., Vergaro, G., Georgiopoulos, G. A., Saccaro, L. F., Lombardi, C., Passino, C., Cerbai, E., Metra, M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.031 · Cited by 107
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium
Abraham, W. T., Psotka, M. A., Fiuzat, M., Filippatos, G. S., Lindenfeld, J. M., Mehran, R., Ambardekar, A. V., Carson, P. E., Jacob, R., Januzzi, J. L., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.10.002 · Cited by 108
Self-citation
National Trends in Outcomes Among Elderly Patients with Heart Failure
Kosiborod, M., Lichtman, J. H., Heidenreich, P. A., Normand, S. T., Wang, Y., Brass, L. M., & Krumholz, H. M. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.11.019 · Cited by 103
Medical advances in the treatment of congestive heart failure.
Armstrong, P. W., & Moe, G. W. P. L. (1993) · Circulation · doi:10.1161/01.cir.88.6.2941 · Cited by 103
Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis
Cleland, J. G. F., Carubelli, V., Castiello, T., Yassin, A., Pellicori, P., & Antony, R. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9306-2 · Cited by 105
Prognosis determination in heart failure
Eichhorn, E. J. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00384-2 · Cited by 102
The paradox of β-adrenergic blockade for the management of congestive heart failure
Eichhorn, E. J. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90750-6 · Cited by 102
Acute and Short-Term Hemodynamic, Echocardiography, and Clinical Effects of Enalapril Maleate in Dogs With Naturally Acquired Heart Failure: Results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril Study: The IMPROVE Study Group
Sisson, D. D. (1995) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.1995.tb01074.x · Cited by 101
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure
Taylor, A. L., Ziesche, S., & Yancy, C. W. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.02.045 · Cited by 101
Self-citation
Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
Massie, B. M., Berk, M. R., Brozena, S. C., Elkayam, U., Plehn, J. F., Kukin, M. L., Packer, M., Murphy, B. E., Neuberg, G. W., & Steingart, R. M. (1993) · Circulation · doi:10.1161/01.cir.88.2.492 · Cited by 101
β-Adrenergic Blockers and Survival in Heart Failure
Pfeffer, M. A., & Stevenson, L. W. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342109 · Cited by 101
Measurement of Strain in the Left Ventricle during Diastole with cine-MRI and Deformable Image Registration
Veress, A. I., Gullberg, G. T., & Weiss, J. A. (2005) · Journal of Biomechanical Engineering · doi:10.1115/1.2073677 · Cited by 100
Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium. An in vitro study under physiological experimental conditions.
Holubarsch, C., Hasenfuss, G. P., Schmidt‐Schweda, S., Knorr, A., Pieske, B. M., Ruf, T., Fasol, R., & Just, H. (1993) · Circulation · doi:10.1161/01.cir.88.3.1228 · Cited by 100
Organic nitrates: Update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction
Münzel, T. F., Steven, S., & Daiber, A. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.09.002 · Cited by 101
Traditional and New Composite Endpoints in Heart Failure Clinical Trials: Facilitating Comprehensive Efficacy Assessments and Improving Trial Efficiency
Anker, S. D., Schroeder, S., Atar, D., Bax, J. J., Ceconi, C., Cowie, M., Crisp, A., Dominjon, F., Ford, I., Ghofrani, H. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.516 · Cited by 108
Management of Heart Failure
Baker, D. W. (1994) · JAMA · doi:10.1001/jama.272.20.1614 · Cited by 99
Atrial natriuretic peptide in heart failure
Brandt, R. R., Wright, R. S., Redfield, M. M., & Burnett, J. C. J. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90468-g · Cited by 99
Electrical and structural remodeling of the failing ventricle
Armoundas, A. A., Wu, R., Juang, G., Marbán, E., & Tomaselli, G. F. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00171-1 · Cited by 98
BiDil: Race Medicine Or Race Marketing?
Sankar, P. L., & Kahn, J. (2005) · Health Affairs · doi:10.1377/hlthaff.w5.455 · Cited by 101
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial
McMurray, J. J. V., Young, J. B., Dunlap, M. E., Granger, C. B., Hainer, J. W., Michelson, E. L., Earle, S., Olofsson, B., Östergren, J., Yusuf, S., et al. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.02.028 · Cited by 98
A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients
Khalil, M. E., Basher, A. W., Brown, E. J., & Alhaddad, I. A. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01229-3 · Cited by 99
Enalapril Treatment Increases Cardiac Performance and Energy Reserve Via the Creatine Kinase Reaction in Myocardium of Syrian Myopathic Hamsters With Advanced Heart Failure
Nascimben, L., Friedrich, J. O., Liao, R., Pauletto, P., Pessina, A. C., & Ingwall, J. S. (1995) · Circulation · doi:10.1161/01.cir.91.6.1824 · Cited by 97
Influence of the Implantable Cardioverter/Defibrillator on Sudden Death and Total Mortality in Patients Evaluated for Cardiac Transplantation
Sweeney, M. O., Ruskin, J. N., Garan, H., McGovern, B. A., Guy, M. L., Torchiana, D. F., Vlahakes, G. J., Newell, J. B., Semigran, M. J., & DEC, G. W. (1995) · Circulation · doi:10.1161/01.cir.92.11.3273 · Cited by 97
Survival after myocardial infarction in rats: captopril versus losartan
Milavetz, J. J., Raya, T. E., Johnson, C. S., Morkin, E., & Goldman, S. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00506-4 · Cited by 97
Self-citation
Acute Myocardial Infarction in Diabetes Mellitus
Nesto, R. W., & ZARICH, S. W. (1998) · Circulation · doi:10.1161/01.cir.97.1.12 · Cited by 97
Rat infarct model of myocardial infarction and heart failure
Goldman, S., & Raya, T. E. (1995) · Journal of Cardiac Failure · doi:10.1016/1071-9164(95)90019-5 · Cited by 96
Self-citation
The pathophysiology of advanced heart failure
Baig, M. K., Mahon, N., McKenna, W. J., Caforio, A. L. P., Bonow, R. O., Francis, G. S., & Gheorghiade, M. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70252-2 · Cited by 97
Self-citation
Cardiovascular consequences of laparoscopic surgery
Struthers, A. D., & Cuschieri, A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11478-7 · Cited by 96
Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy
Grinstead, W. C., Francis, M. J., Marks, G. F., Tawa, C. B., Zoghbi, W. A., & Young, J. B. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90815-x · Cited by 96
Progress in Heart Failure Management?
Konstam, M. A. (2000) · Circulation · doi:10.1161/01.cir.102.10.1076 · Cited by 96
Evaluation and Monitoring of Patients with Acute Heart Failure Syndromes
Nohria, A., Mielniczuk, L. M., & Stevenson, L. W. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.019 · Cited by 95
Mechanical Device–Based Methods of Managing and Treating Heart Failure
MANCINI, D. M., & Burkhoff, D. (2005) · Circulation · doi:10.1161/circulationaha.104.481259 · Cited by 95
Does the Collaborative Model Improve Care for Chronic Heart Failure?
Asch, S. M., Baker, D. W., KEESEY, J. W., Broder, M. S., Schonlau, M., Rosen, M., Wallace, P., & Keeler, E. B. (2005) · Medical Care · doi:10.1097/01.mlr.0000167182.72251.a1 · Cited by 95

Authors: Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., Bhat, G., Goldman, S., Fletcher, R. D., Doherty, J., Hughes, C. V., Carson, P., Cintron, G., Shabetai, R., & Haakenson, C.
Affiliations: University of Minnesota (US)
ORCID: Cohn, Jay N.
Johnson, Gary
Bhat, Geetha
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1991-08
Volume: 325
Issue: 5
Pages: 303-310
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199108013250502
OpenAlex: W2046383587
Cited by: 2,833
References: 19
Citations by year: 2026: 14 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 27 · 2020: 46 · 2019: 39 · 2018: 51 · 2017: 56 · 2016: 69 · 2015: 59 · 2014: 54 · 2013: 61 · 2012: 56
FWCI: 124.25
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords: enalapril, hydralazine, isosorbide dinitrate, chronic congestive heart failure, vasodilator therapy, mortality, sudden death, exercise oxygen consumption, left ventricular ejection fraction, ACE inhibitors, combination therapy, digoxin, diuretics, NYHA functional class
MeSH terms: Adolescent, Adult, Aged, Chronic Disease, Death, Sudden, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Enalapril, Physical Exertion, Heart Failure, Hospitalization, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Norepinephrine, Oxygen Consumption, Patient Compliance, Stroke Volume, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks